Wnt/beta-catenin/Tcf signaling: A critical pathway in gastrointestinal tumorigenesis

Digestion

Volumn 66, Issue 3, 2002, Pages 131-144

  Kolligs, Frank T ^a   Bommer, Guido ^b   Göke, Burkhard ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Catenin; Adenomatous polyposis coli; Colorectal cancer; Gastrointestinal cancer; T cell factor; Wnt

Indexed keywords

AXIN; BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; MATRILYSIN; NUCLEASE; PROTEIN; PROTEIN P53; WNT PROTEIN;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CLINICAL PATHWAY; COLON ADENOMA; COLON POLYPOSIS; COLORECTAL CANCER; DEREGULATION; DIGESTIVE SYSTEM CANCER; GENE MUTATION; GENE TARGETING; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC STRAIN; GENETIC TRANSCRIPTION; HEPATOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR SUPPRESSOR GENE; WESTERN HEMISPHERE;

BETA CATENIN; COLORECTAL NEOPLASMS; CYTOSKELETAL PROTEINS; GASTROINTESTINAL NEOPLASMS; HUMANS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; WNT PROTEINS; ZEBRAFISH PROTEINS;

EID: 0036953625     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066755     Document Type: Review

References (219)

1. Funayama N, Fagotto F, McCrea P, Gumbiner BM: Embryonic axis induction by the armadillo repeat domain of beta-catenin: Evidence for intracellular signaling. J Cell Biol 1995;128:959-968.
2. Cadigan KM, Nusse R: Wnt signaling: A common theme in animal development. Genes Dev 1997;11:3286-3305.
3. Willert K, Nusse R: Beta-catenin: A key mediator of Wnt signaling. Curr Opin Genet Dev 1998;8:95-102.
4. Arias AM, Brown AM, Brennan K: Wnt signalling: Pathway or network? Curr Opin Genet Dev 1999;9:447-454.
5. Polakis P: Wnt signaling and cancer. Genes Dev 2000;14:1837-1851.
6. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512.
7. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-5527.
8. Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426.
9. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-2891.
10. Koh TJ, Bulitta CJ, Fleming JV, Dockray GJ, Varro A, Wang TC: Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 2000;106:533-539.
11. Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y, Smith IM, Wu R, Zhai Y, Cho KR, Fearon ER: ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell 2002;1:145-155.
12. Miller JR, Hocking AM, Brown JD, Moon RT: Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene 1999;18:7860-7872.
13. Bienz M, Clevers H: Linking colorectal cancer to Wnt signaling. Cell 2000;103:311-320.
14. Fodde R, Smits R, Clevers H: APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001;1:55-67.
15. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
16. Renan MJ: How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinog 1993;7:139-146.
17. Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
18. Wodarz A, Nusse R: Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 1998;14:59-88.
19. Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, Hess F, Saint-Jeannet JP, He X: LDL-receptor-related proteins in Wnt signal transduction. Nature 2000;407:530-535.
20. Wehrli M, Dougan ST, Caldwell K, O'Keefe L, Schwartz S, Vaizel-Ohayon D, Schejter E, Tomlinson A, DiNardo S: Arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature 2000;407:527-530.
21. Nusse R: Developmental biology. Making head or tail of Dickkopf. Nature 2001;411:255-256.
22. Leyns L, Bouwmeester T, Kim SH, Piccolo S, De Robertis EM: Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 1997;88:747-756.
23. Wang S, Krinks M, Lin K, Luyten FP, Moos M Jr: Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell 1997;88:757-766.
24. Wang S, Krinks M, Moos M Jr: Frzb-1, an antagonist of Wnt-1 and Wnt-8, does not block signaling by Wnts -3A, -5A, or -11. Biochem Biophys Res Commun 1997;236:502-504.
25. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA: Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem 1999;274:16180-187.
26. Melkonyan HS, Chang WC, Shapiro JP, Mahadevappa M, Fitzpatrick PA, Kiefer MC, Tomei LD, Umansky SR: SARPs: A family of secreted apoptosis-related proteins. Proc Natl Acad Sci USA 1997;94:13636-13641.
27. Tanaka S, Akiyoshi T, Mori M, Wands JR, Sugimachi K: A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals. Proc Natl Acad Sci USA 1998;95:10164-10169.
28. Axelrod JD, Miller JR, Shulman JM, Moon RT, Perrimon N: Differential recruitment of Dishevelled provides signaling specificity in the planar cell polarity and Wingless signaling pathways. Genes Dev 1998;12:2610-2622.
29. Lee JS, Ishimoto A, Yanagawa S: Characterization of mouse dishevelled (Dvl) proteins in Wnt/Wingless signaling pathway. J Biol Chem 1999;274:21464-1470.
30. Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H, Fryer LG, Hutchinson L, Fry MJ, Dale TC: Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF- dependent transcription. EMBO J 1999; 18:2823-2835.
31. Boutros M, Mihaly J, Bouwmeester T, Mlodzik M: Signaling specificity by Frizzled receptors in Drosophila. Science 2000;288:1825-1828.
32. Noordermeer J, Klingensmith J, Perrimon N, Nusse R: Dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature 1994;367:80-83.
33. Li L, Yuan H, Xie W, Mao J, Caruso AM, McMahon A, Sussman DJ, Wu D: Dishevelled proteins lead to two signaling pathways. Regulation of LEF-1 and c-Jun N-terminal kinase in mammalian cells. J Biol Chem 1999;274:129-134.
34. Moriguchi T, Kawachi K, Kamakura S, Masuyama N, Yamanaka H, Matsumoto K, Kikuchi A, Nishida E: Distinct domains of mouse dishevelled are responsible for the c-Jun N-terminal kinase/stress-activated protein kinase activation and the axis formation in vertebrates. J Biol Chem 1999;274:30957-30962.
35. McEwen DG, Peifer M: Wnt signaling: The naked truth? Curr Biol 2001;11:R524-R526.
36. Kishida M, Koyama S, Kishida S, Matsubara K, Nakashima S, Higano K, Takada R, Takada S, Kikuchi A: Axin prevents Wnt-3a-induced accumulation of beta-catenin. Oncogene 1999; 18:979-985.
37. Willert K, Brink M, Wodarz A, Varmus H, Nusse R: Casein kinase 2 associates with and phosphorylates dishevelled. EMBO J 1997;16: 3089-3096.
38. Song DH, Sussman DJ, Seldin DC: Endogenous protein kinase CK2 participates in Wnt signaling in mammary epithelial cells. J Biol Chem 2000;275:23790-23797.
39. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002;108:837-847.
40. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, Alkalay I: Axin-mediated CKI phosphorylation of beta-catenin at Ser 45:A molecular switch for the Wnt pathway. Genes Dev 2002;16:1066-1076.
41. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y: Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 1998;396:590-594.
42. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, Perret C, Rubinfeld B, Margottin F, Benarous R, Polakis P: The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell. Curr Biol 1999;9:207-210.
43. Kitagawa M, Hatakeyama S, Shirane M, Matsumoto M, Ishida N, Hattori K, Nakamichi I, Kikuchi A, Nakayama K, Nakayama K: An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 1999;18:2401-2410.
44. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW: The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999;13:270-283.
45. Maniatis T: A ubiquitin ligase complex essential for the NF-kappaB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev 1999;13:505-510.
46. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R: Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16: 3797-3804.
47. van Noort M, van de Wetering M, Clevers H: Identification of two novel regulated serines in the N terminus of beta-catenin. Exp Cell Res 2002;276:264-272.
48. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A: Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 1999;274:10681-10684.
49. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P: Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996;272:1023-1026.
50. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT: The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10:1443-1454.
51. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A: Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998;17:1371-1384.
52. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, Kikuchi A: Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998;273:10823-10826.
53. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P: Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998;8:573-581.
54. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D, Birchmeier W: Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998;280:596-599.
55. Hsu W, Zeng L, Costantini F: Identification of a domain of Axin that binds to the serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem 1999;274:3439-3445.
56. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, Kawasoe T, Ishiguro H, Fujita M, Tokino T, Sasaki Y, Imaoka S, Murata M, Shimano T, Yamaoka Y, Nakamura Y: AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000; 24:245-250.
57. Liu W, Dong X, Mai M, Seelan RS, Taniguchi K, Krishnadath KK, Halling KC, Cunningham JM, Boardman LA, Qian C, Christensen E, Schmidt SS, Roche PC, Smith DI, Thibodeau SN: Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 2000;26:146-147.
58. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998;58:1130-1134.
59. Sutherland C, Leighton IA, Cohen P: Inactivation of glycogen synthase kinase-3 beta by phosphorylation: New kinase connections in insulin and growth-factor signalling. Biochem J 1993;296:15-19.
60. Li L, Yuan H, Weaver CD, Mao J, Farr GH 3rd, Sussman DJ, Jonkers J, Kimelman D, Wu D: Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J 1999;18:4233-4240.
61. Porter AC, Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998;17:1343-1352.
62. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP: Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol 1999;145:699-711.
63. Kim E, Arnould T, Sellin LK, Benzing T, Fan MJ, Gruning W, Sokol SY, Drummond I, Walz G: The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 1999;274:4947-4953.
64. Lawlor MA, Alessi DR: PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001;114:2903-2910.
65. Scheid MP, Woodgett JR: PKB/AKT: Functional insights from genetic models. Nat Rev Mol Cell Biol 2001;2:760-768.
66. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, Karl RC, Coppola D: Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999;30: 1128-1133.
67. Davidson LA, Jiang YH, Derr JN, Aukema HM, Lupton JR, Chapkin RS: Protein kinase C isoforms in human and rat colonic mucosa. Arch Biochem Biophys 1994;312:547-553.
68. Pongracz J, Clark P, Neoptolemos JP, Lord JM: Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 1995;61:35-39.
69. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M, et al: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991;66:589-600.
70. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D, et al: Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-665.
71. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, et al: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991;251:1366-1370.
72. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
73. Lal G, Gallinger S: Familial adenomatous polyposis. Semin Surg Oncol 2000;18:314-323.
74. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P: Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995;92:3046-3050.
75. Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P: Association of the APC gene product with beta-catenin. Science 1993;262:1731-1734.
76. Su LK, Vogelstein B, Kinzler KW: Association of the APC tumor suppressor protein with catenins. Science 1993;262:1734-1737.
77. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y: Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229-233.
78. Rubinfeld B, Albert I, Porfiri E, Munemitsu S, Polakis P: Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Res 1997;57:4624-4630.
79. Hulsken J, Behrens J, Birchmeier W: Tumor-suppressor gene products in cell contacts: The cadherin-APC-armadillo connection. Curr Opin Cell Biol 1994;6:711-716.
80. Hulsken J, Birchmeier W, Behrens J: E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. J Cell Biol 1994;127:2061-2069.
81. Rubinfeld B, Souza B, Albert I, Munemitsu S, Polakis P: The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin. J Biol Chem 1995;270:5549-5555.
82. Smith KJ, Levy DB, Maupin P, Pollard TD, Vogelstein B, Kinzler KW: Wild-type but not mutant APC associates with the microtubule cytoskeleton. Cancer Res 1994;54:3672-3675.
83. Munemitsu S, Souza B, Muller O, Albert I, Rubinfeld B, Polakis P: The APC gene product associates with microtubules in vivo and promotes their assembly in vitro. Cancer Res 1994;54:3676-3681.
84. Su LK, Burrell M, Hill DE, Gyuris J, Brent R, Wiltshire R, Trent J, Vogelstein B, Kinzler KW: APC binds to the novel protein EB1. Cancer Res 1995;55:2972-2977.
85. Matsumine A, Ogai A, Senda T, Okumura N, Satoh K, Baeg GH, Kawahara T, Kobayashi S, Okada M, Toyoshima K, Akiyama T: Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein. Science 1996;272:1020-1023.
86. Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y, Higuchi O, Akiyama T: Asef, a link between the tumor suppressor APC and G-protein signaling. Science 2000;289:1194-1197.
87. Matsuzawa SI, Reed JC: Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001;7:915-926.
88. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neu-feld KL, White RL, Matsunami N: Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001;7:927-936.
89. Kawahara K, Morishita T, Nakamura T, Hamada F, Toyoshima K, Akiyama T: Down-regulation of beta-catenin by the colorectal tumor suppressor APC requires association with Axin and beta-catenin. J Biol Chem 2000;275:8369-8374.
90. Hu G, Zhang S, Vidal M, Baer JL, Xu T, Fearon ER: Mammalian homologs of seven in absentia regulate DCC via the ubiquitin-proteasome pathway. Genes Dev 1997;11:2701-2714.
91. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-1790.
92. Kitaeva MN, Grogan L, Williams JP, Dimond E, Nakahara K, Hausner P, DeNobile JW, Soballe PW, Kirsch IR: Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res 1997;57:4478-4481.
93. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y: Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 1998;58:1021-1026.
94. Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bapat B, Gallinger S, Redston M: Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 1999;59:3346-3351.
95. Polakis P, Hart M, Rubinfeld B: Defects in the regulation of beta-catenin in colorectal cancer. Adv Exp Med Biol 1999;470:23-32.
96. Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML: Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999;59:1442-1444.
97. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ: Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997;151:329-334.
98. Shitoh K, Konishi F, Iijima T, Ohdaira T, Sakai K, Kanazawa K, Miyaki M: A novel case of a sporadic desmoid tumour with mutation of the beta catenin gene. J Clin Pathol 1999;52:695-696.
99. Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ, Alman BA: Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene 1999;18:6615-6620.
100. Deka J, Kuhlmann J, Muller O: A domain within the tumor suppressor protein APC shows very similar biochemical properties as the microtubule-associated protein tau. Eur J Biochem 1998;253:591-597.
101. Askham JM, Moncur P, Markham AF, Morrison EE: Regulation and function of the interaction between the APC tumour suppressor protein and EB1. Oncogene 2000;19:1950-1958.
102. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH, Clevers H: Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 2001;3: 433-438.
103. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS: A role for the adenomatous polyposis coli protein in chromosome segregation. Nat Cell Biol 2001;3:429-432.
104. Peifer M, Wieschaus E: The segment polarity gene armadillo encodes a functionally modular protein that is the Drosophila homolog of human plakoglobin. Cell 1990;63:1167-1176.
105. Peifer M, Rauskolb C, Williams M, Riggleman B, Wieschaus E: The segment polarity gene armadillo interacts with the wingless signaling pathway in both embryonic and adult pattern formation. Development 1991;111:1029-1043.
106. Barth AI, Nathke IS, Nelson WJ: Cadherins, catenins and APC protein: Interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997;9:683-690.
107. Huber O, Bierkamp C, Kemler R: Cadherins and catenins in development. Curr Opin Cell Biol 1996;8:685-691.
108. Muller T, Choidas A, Reichmann E, Ullrich A: Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem 1999;274:10173-10183.
109. Hazan RB, Norton L: The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J Biol Chem 1998;273:9078-9084.
110. Hiscox S, Jiang WG: Hepatocyte growth factor/scatter factor disrupts epithelial tumour cell-cell adhesion: Involvement of beta-catenin. Anticancer Res 1999;19:509-517.
111. Hiscox S, Jiang WG: Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999;261:406-411.
112. Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S: c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 1995;208:1067-1072.
113. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H: Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-1787.
114. Kolligs FT, Hu G, Dang CV, Fearon ER: Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 1999;19:5696-5706.
115. Orford K, Orford CC, Byers SW: Exogenous expression of beta-catenin regulates contact inhibition, anchorage-independent growth, anoikis, and radiation-induced cell cycle arrest. J Cell Biol 1999;146:855-868.
116. Gat U, DasGupta R, Degenstein L, Fuchs E: De Novo hair follicle morphogenesis and hair tumors in mice expressing a truncated beta-catenin in skin. Cell 1998;95:605-614.
117. Romagnolo B, Berrebi D, Saadi-Keddoucci S, Porteu A, Pichard AL, Peuchmaur M, Vandewalle A, Kahn A, Perret C: Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated beta-catenin. Cancer Res 1999;59:3875-3879.
118. Chan EF: Pilomatricomas contain activating mutations in beta-catenin. J Am Acad Dermatol 2000;43:701-702.
119. Chan EF, Gat U, McNiff JM, Fuchs E: A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet 1999;21:410-413.
120. Miyaki M, Iijima T, Kimura J, Yasuno M, Mori T, Hayashi Y, Koike M, Shitara N, Iwama T, Kuroki T: Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. Cancer Res 1999; 59:4506-4509.
121. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T: Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999;59:269-273.
122. Jeng YM, Wu MZ, Mao TL, Chang MH, Hsu HC: Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000;152:45-51.
123. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, Buendia MA: Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000;19:498-504.
124. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95:8847-8851.
125. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y: Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58:2524-2527.
126. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA: Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155:703-710.
127. Legoix P, Bluteau O, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, Laurent-Puig P, Zucman-Rossi J: Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999;18:4044-4046.
128. Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, Ohgaki H: Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155:1795-1801.
129. Choi YW, Heath EI, Heitmiller R, Forastiere AA, Wu TT: Mutations in beta-catenin and APC genes are uncommon in esophageal and esophagogastric junction adenocarcinomas. Mod Pathol 2000;13:1055-1059.
130. Wijnhoven BP, Nollet F, De Both NJ, Tilanus HW, Dinjens WN: Genetic alterations involving exon 3 of the beta-catenin gene do not play a role in adenocarcinomas of the esophagus. Int J Cancer 2000;86:533-537.
131. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J: Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000;114:583-590.
132. Osterheld MC, Bian YS, Bosman FT, Benhattar J, Fontolliet C: Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol 2002;117:451-456.
133. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J: Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: Correlation with disease progression and dedifferentiation. Am J Pathol 1998;152:135-144.
134. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY: Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res 1999;59:4257-4260.
135. Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, Hirohashi S: Beta-catenin mutations in sporadic fundic gland polyps. Virchows Arch 2002;440:381-386.
136. Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A, Rimm DL, Costa J, Fearon ER: Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 1999;10:369-376.
137. Gerdes B, Ramaswamy A, Simon B, Pietsch T, Bastian D, Kersting M, Moll R, Bartsch D: Analysis of beta-catenin gene mutations in pancreatic tumors. Digestion 1999;60:544-548.
138. Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, Cameron JL, Hruban RH: Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: Frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 2001;159: 1619-1627.
139. Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, Brennan M, Cameron JL, Klimstra DS: Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: Frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 2002;160:953-962.
140. Abraham SC, Klimstra DS, Wilentz RE, Yeo CJ, Conlon K, Brennan M, Cameron JL, Wu TT, Hruban RH: Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol 2002;160:1361-1369.
141. Yanagisawa N, Mikami T, Saegusa M, Okayasu I: More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages. Cancer Res 2001;61:19-22.
142. Chang HJ, Jee CD, Kim WH: Mutation and altered expression of beta-cduring gallbladder carcinogenesis. Am J Surg Pathol 2002;26:758-766.
143. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M: Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001;14:900-905.
144. Rashid A, Gao YT, Bhakta S, Shen MC, Wang BS, Deng J, Fraumeni JF Jr, Hsing AW: Beta-catenin mutations in biliary tract cancers: A population-based study in China. Cancer Res 2001;61:3406-3409.
145. Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S: Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-3528.
146. Palacios J, Gamallo C: Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-1347.
147. Gamallo C, Palacios J, Moreno G, Calvo de Mora J, Suarez A, Armas A: Beta-catenin expression pattern in stage I and II ovarian carcinomas: Relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. Am J Pathol 1999;155:527-536.
148. Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, Ward B, Cummings M, Chenevix-Trench G: Beta-catenin mutation and expression analysis in ovarian cancer: Exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 1999;82:625-629.
149. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER: Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999;154:325-329.
150. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL: Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999;59:1811-1815.
151. Voeller HJ, Truica CI, Gelmann EP: Beta-catenin mutations in human prostate cancer. Cancer Res 1998;58:2520-2523.
152. Koesters R, Ridder R, Kopp-Schneider A, Betts D, Adams V, Niggli F, Briner J, von Knebel Doeberitz M: Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res 1999;59:3880-3882.
153. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J: Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. Genes Chromosomes Cancer 2001;30:316-321.
154. Zurawel RH, Chiappa SA, Allen C, Raffel C: Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 1998; 58:896-899.
155. Ben-Ze'ev A, Geiger B: Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr Opin Cell Biol 1998;10:629-639.
156. Shibata T, Gotoh M, Ochiai A, Hirohashi S: Association of plakoglobin with APC, a tumor suppressor gene product, and its regulation by tyrosine phosphorylation. Biochem Biophys Res Commun 1994;203:519-522.
157. Kodama S, Ikeda S, Asahara T, Kishida M, Kikuchi A: Axin directly interacts with plakoglobin and regulates its stability. J Biol Chem 1999;274:27682-27688.
158. Miravet S, Piedra J, Miro F, Itarte E, Garcia de Herreros A, Dunach M: The transcriptional factor Tcf-4 contains different binding sites for beta-catenin and plakoglobin. J Biol Chem 2002;277:1884-1891.
159. Simcha I, Shtutman M, Salomon D, Zhurinsky J, Sadot E, Geiger B, Ben-Ze'ev A: Differential nuclear translocation and transactivation potential of beta-catenin and plakoglobin. J Cell Biol 1998;141:1433-1448.
160. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, Fearon ER: Gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev 2000;14:1319-1331.
161. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W: Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382:638-642.
162. Molenaar M, van de Wetering M, Oosterwegel M, Peterson-Maduro J, Godsave S, Korinek V, Roose J, Destree O, Clevers H: XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 1996;86:391-399.
163. Hecht A, Vleminckx K, Stemmler MP, van Roy F, Kemler R: The p300/CBP
164. Sun Y, Kolligs FT, Hottiger MO, Mosavin R, Fearon ER, Nabel GJ: Regulation of beta-catenin transformation by the p300 transcriptional coactivator. Proc Natl Acad Sci USA 2000;97:12613-12618.
165. Takemaru KI, Moon RT: The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 2000;149:249-254.
166. Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H: The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J 2001;20:4935-4943.
167. Bauer A, Huber O, Kemler R: Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein. Proc Natl Acad Sci USA 1998;95:14787-14792.
168. Morin PJ: Beta-catenin signaling and cancer. Bioessays 1999;21:1021-1030.
169. Duval A, Iacopetta B, Ranzani GN, Lothe RA, Thomas G, Hamelin R: Variable mutation frequencies in coding repeats of TCF-4 and other target genes in colon, gastric and endometrial carcinoma showing microsatellite instability. Oncogene 1999;18:6806-6809.
170. Duval A, Gayet J, Zhou XP, Iacopetta B, Thomas G, Hamelin R: Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Res 1999;59:4213-4215.
171. Duval A, Rolland S, Tubacher E, Bui H, Thomas G, Hamelin R: The human T-cell transcription factor-4 gene: Structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines. Cancer Res 2000;60:3872-3879.
172. Roose J, Clevers H: TCF transcription factors: Molecular switches in carcinogenesis. Biochim Biophys Acta 1999;1424:M23-M37.
173. Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P, van de Wetering M, Destree O, Clevers H: The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors. Nature 1998;395:608-612.
174. Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A: Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 1998;395:604-608.
175. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence Marsh J, Holcombe RF, Waterman ML: Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 2001;28:53-57.
176. Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, Watson J: C-myc oncogene expression in colorectal cancer. Cancer 1987; 59:1289-1295.
177. Erisman MD, Scott JK, Watt RA, Astrin SM: The c-myc protein is constitutively expressed at elevated levels in colorectal carcinoma cell lines. Oncogene 1988;2:367-378.
178. Finley GG, Schulz NT, Hill SA, Geiser JR, Pipas JM, Meisler AI: Expression of the myc gene family in different stages of human colorectal cancer. Oncogene 1989;4:963-971.
179. Imaseki H, Hayashi H, Taira M, Ito Y, Tabata Y, Onoda S, Isono K, Tatibana M: Expression of c-myc oncogene in colorectal polyps as a biological marker for monitoring malignant potential. Cancer 1989;64:704-709.
180. Smith DR, Myint T, Goh HS: Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 1993;68:407-413.
181. Erisman MD, Rothberg PG, Diehl RE, Morse CC, Spandorfer JM, Astrin SM: Deregulation of c-myc gene expression in human colon carcinoma is not accompanied by amplification or rearrangement of the gene. Mol Cell Biol 1985;5:1969-1976.
182. Kamb A: Role of a cell cycle regulator in hereditary and sporadic cancer. Cold Spring Harb Symp Quant Biol 1994;59:39-47.
183. Ohhara M, Esumi M, Kurosu Y: Activation but not inactivation of the MTS1 gene is associated with primary colorectal carcinomas. Biochem Biophys Res Commun 1996;226:791-795.
184. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677.
185. Sellers WR, Kaelin WG Jr: Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol 1997;15:3301-3312.
186. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T: Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999;155:1033-1038.
187. Wilson CL, Heppner KJ, Labosky PA, Hogan BL, Matrisian LM: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94:1402-1407.
188. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ: WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 2000; 14:585-595.
189. Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R, Logtenberg T, Clevers H: Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 1999;285:1923-1926.
190. Yan D, Wiesmann M, Rohan M, Chan V, Jefferson AB, Guo L, Sakamoto D, Caothien RH, Fuller JH, Reinhard C, Garcia PD, Randazzo FM, Escobedo J, Fantl WJ, Williams LT: Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumors. Proc Natl Acad Sci USA 2001;98:14973-14978.
191. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F: Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002;22:1172-1183.
192. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J: Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002;22:1184-1193.
193. Leung JY, Kolligs FT, Wu R, Zhai Y, Kuick R, Hanash S, Cho KR, Fearon ER: Activation of AXIN2 expression by beta-catenin/TCF: A feedback repressor pathway regulating Wnt signaling. J Biol Chem 2002;277:21657-21665.
194. van der Heyden MA, Rook MB, Hermans MM, Rijksen G, Boonstra J, Defize LH, Destree OH: Identification of connexin43 as a functional target for Wnt signalling. J Cell Sci 1998;111:1741-1749.
195. Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ, Phillips WA: Id2 is a target of the beta-catenin/T cell factor pathway in colon carcinoma. J Biol Chem 2001;276:45113-45119.
196. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARdelta is an APC-regulated target of non-steroidal anti-inflammatory drugs. Cell 1999; 99:335-345.
197. Zhang T, Otevrel T, Gao Z, Gao Z, Ehrlich SM, Fields JZ, Boman BM: Evidence that APC regulates survivin expression: A possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61: 8664-8667.
198. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C: Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96:1603-1608.
199. Ishiguro H, Furukawa Y, Daigo Y, Miyoshi Y, Nagasawa Y, Nishiwaki T, Kawasoe T, Fujita M, Satoh S, Miwa N, Fujii Y, Nakamura Y: Isolation and characterization of human NBL4, a gene involved in the beta-catenin/tcf signaling pathway. Jpn J Cancer Res 2000;91: 597-603.
200. Kawasoe T, Furukawa Y, Daigo Y, Nishiwaki T, Ishiguro H, Fujita M, Satoh S, Miwa N, Nagasawa Y, Miyoshi Y, Ogawa M, Nakamura Y: Isolation and characterization of a novel human gene, DRCTNNB1A, the expression of which is down-regulated by beta-catenin. Cancer Res 2000;60:3354-3358.
201. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S: Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000;60:4761-4766.
202. Arnold SJ, Stappert J, Bauer A, Kispert A, Herrmann BG, Kemler R: Brachyury is a target gene of the Wnt/beta-catenin signaling pathway. Mech Dev 2000;91:249-258.
203. van der Luijt R, Khan PM, Vasen H, van Leeuwen C, Tops C, Roest P, den Dunnen J, Fodde R: Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics 1994;20:1-4.
204. Ballhausen WG: Genetic testing for familial adenomatous polyposis. Ann NY Acad Sci 2000;910:36-49.
205. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN, Shuber AP: Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-1227.
206. Zhou W, Goodman SN, Galizia G, Lieto E, Ferraraccio F, Pignatelli C, Purdie CA, Piris J, Morris R, Harrison DJ, Paty PB, Culliford A, Romans KE, Montgomery EA, Choti MA, Kinzler KW, Vogelstein B: Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 2002;359:219-225.
207. Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR: Cadherin-catenin expression in primary colorectal cancer: A survival analysis. Br J Cancer 1999;80:1046-1051.
208. Maruyama K, Ochiai A, Akimoto S, Nakamura S, Baba S, Moriya Y, Hirohashi S: Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology 2000;59:302-309.
209. Ougolkov AV, Yamashita K, Mai M, Minamoto T: Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002;122:60-71.
210. Hsu HC, Jeng YM, Mao TL, Chu JS, Lai PL, Peng SY: Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000; 157:763-770.
211. Mao TL, Chu JS, Jeng YM, Lai PL, Hsu HC: Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101.
212. Grabsch H, Takeno S, Noguchi T, Hommel G, Gabbert HE, Mueller W: Different patterns of beta-catenin expression in gastric carcinomas: Relationship with clinicopathological parameters and prognostic outcome. Histopathology 2001;39:141-149.
213. Nakanishi Y, Ochiai A, Akimoto S, Kato H, Watanabe H, Tachimori Y, Yamamoto S, Hirohashi S: Expression of E-cadherin, alpha-catenin, beta-catenin and plakoglobin in esophageal carcinomas and its prognostic significance: Immunohistochemical analysis of 96 lesions. Oncology 1997;54:158-165.
214. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Kremers ED, Dinjens WN, Bosman FT: Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997;182:331-338.
215. Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW: The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Res 2000;60:1671-1676.
216. Roh H, Green DW, Boswell CB, Pippin JA, Drebin JA: Suppression of beta-catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 2001;61:6563-6568.
217. Chen RH, McCormick F: Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells. Cancer Res 2001;61:4445-4449.
218. Lipinski KS, Djeha AH, Ismail T, Mountain A, Young LS, Wrighton CJ: High-level, beta-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol Ther 2001;4:365-371.
219. Korinek V, Barker N, Moerer P, van Donselaar E, Huls G, Peters PJ, Clevers H: Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 1998;19:379-383.